Cutaneous dermatomyositis disease course followed over time using the Cutaneous Dermatomyositis Disease Area and Severity Index - 16/08/18
Abstract |
Background |
Limited studies describe the longitudinal course of cutaneous dermatomyositis (DM).
Objective |
To characterize disease course in treated cutaneous DM by using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), a validated outcome instrument.
Methods |
A retrospective cohort included patients with DM who had their CDASI activity subscore recorded for at least 2 years. Disease progression was classified as improved, worsened, or stable, and disease course was classified as monophasic, polyphasic, or chronic. Subjects were divided into groups with disease of mild (n = 16) and moderate-to-severe (n = 24) baseline severity.
Results |
A total of 40 patients with DM met inclusion criteria. The majority demonstrated improvement in disease activity (n = 21 [52.5%]) rather than worsening (n = 7 [17.5%]) and stable (n = 12 [30.0%]) disease. Most patients with mild disease remained stable (n = 10 [62.5%]), whereas most with moderate-to-severe disease improved (n = 19 [79.2%]). A polyphasic course (n = 33 [82.5%]) predominated over monophasic (n = 5 [12.5%]) and chronic (n = 2 [5%]) courses. The average number of flares per year per number of years of follow-up was independent of baseline disease activity.
Limitations |
The retrospective design, potential referral bias, and cutoff values in classification criteria are limitations.
Conclusion |
Baseline CDASI activity score is associated with particular patterns of disease course and progression in cutaneous DM.
Le texte complet de cet article est disponible en PDF.Key words : cutaneous, Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), dermatomyositis, disease activity, disease course, longitudinal, skin predominant
Abbreviations used : ACS, CDASI, DM
Plan
| Supported in part by the National Institutes of Health (NIH) T32 Dermatology Research Training Grant (grant 2T32AR007465-31), NIH grant R21 AR066286, and Pfizer Corporation. We are indebted to the Department of Veterans Affairs Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. The funder/sponsor was not involved in this study. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH. |
|
| Conflicts of interest: None disclosed. |
|
| Reprints not available from the authors. |
Vol 79 - N° 3
P. 464 - septembre 2018 Retour au numéro
Article précédent
- Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: Results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trial
- Sabine Steinke, Claudia Zeidler, Claudia Riepe, Philipp Bruland, Iñaki Soto-Rey, Michael Storck, Matthias Augustin, Svetlana Bobko, Simone Garcovich, Franz J. Legat, Andrey Lvov, Laurent Misery, Nani Osada, Adam Reich, Ekin ?avk, Esther Serra-Baldrich, Markus Streit, Jacek C. Szepietowski, Wolfgang Weger, Martin Dugas, Sonja Ständer
- Objective outcome measures: Collecting meaningful data on alopecia areata
- Elise A. Olsen, Janet Roberts, Leonard Sperling, Antonella Tosti, Jerry Shapiro, Amy McMichael, Wilma Bergfeld, Valerie Callender, Paradi Mirmirani, Ken Washenik, David Whiting, George Cotsarelis, Maria Hordinsky
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?